TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Above the Cuff Suctioning During General Anesthesia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Scheduled for elective abdominal surgery with an anticipated duration longer than 2 hours.~* ASA (American Society of Anesthesiologists) Physical status Classification 1 to 3. (1 - normal healthy patient, 2 - patients with mild systemic disease, 3 - patients with severe systemic disease)~* Endotracheal intubation anticipated to be routine (not difficult) based upon preoperative airway assessment~Exclusion Criteria:~* Short duration surgery (anticipated \< 2 hours) or emergency (non-elective) surgery~* ASA Physical status Classification 4 to 5. (4 - patients with severe systemic diseases that is a constant threat to life, 5 - Moribund patients who are not expected to survive without the operation)~* Anticipated difficult airway requiring technique other than direct laryngoscopy for intubation of the trachea.~* Pregnancy~* History of allergic reaction to Methylene Blue medication~* Methemoglobinemia, glucose-6-phosphate dehydrogenase (G6PD) deficiency~* History of symptomatic chronic obstructive pulmonary disease (asthma, bronchitis, emphysema) or recent pneumonia (\< 6 months prior to surgery).~* Hypoxemia (hemoglobin oxygen saturation \< 90% room air or on O2 at home or in hospital)~* History of coagulopathy, IV heparin therapy, or coumadin therapy (INR \> 2.5)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TaperGuard Evac ETT (Type: EXPERIMENTAL): Trachea will be intubated with Mallinckrodt™TaperGuard™ Evac Endotracheal Tube with a suction port to facilitate removal of secretions from the region of the trachea below the vocal cords and above the inflated ETT cuff
- Teleflex ISIS ETT (Type: EXPERIMENTAL): Trachea will be intubated with Teleflex ISIS HVT Cuffed Tracheal Tube with Subglottic Secretion suction port to facilitate removal of secretions from the region of the trachea below the vocal cords and above the inflated ETT cuff
- Standard ETT (Type: ACTIVE_COMPARATOR): Control group of patients will be intubated with a standard ETT without a suction port above the cuff (The Mallinckrodt Intermediate Hi-Lo Endotracheal Tube)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study Investigating Effects of Foliglurax in Patients With Parkinson's Disease (PD) and Healthy Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Healthy subjects~* The subject has an acceptable resting EEG at the Screening Visit, as judged by the investigator~* The subject is, in the opinion of the investigator, generally healthy based on the assessment of medical history, physical examination, vital signs, body weight, ECG, and the results of the haematology, clinical chemistry, urinalysis, serology, and other laboratory tests.~Patients with PD~* The patient has an acceptable resting EEG performed at the screening period, as judged by the investigator.~* The patient is, in the opinion of the investigator, fit for enrolment in the study based on the assessment of medical history, physical examination, vital signs, body weight, ECG, and the results of the haematology, clinical chemistry, urinalysis, serology, and other laboratory tests.~* The patient has been diagnosed with idiopathic PD for ≥3 years, with a current disease severity of 2 to 4 on the modified Hoehn and Yahr scale in the 'off' state.~* The patient has dyskinesia that is not too severe to cause discomfort for the patient during the EEG assessments~Exclusion criteria:~* The subject has taken disallowed medication \<1 week prior to the first dose of Investigational Medicinal Product (IMP) or \<5 half-lives prior to the Screening Visit for any medication taken.~* The subject has significant alcohol consumption~* The subject has taken any investigational medicinal product \<3 months prior to the first dose of IMP.~* The subjects has a known genetic disorder of human UDPglucoronosyltransferase~* The subject is pregnant or breastfeeding.~Other in- and exclusion criteria may apply

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 70 Years
- Healthy Volunteers: t

Study Arms:
- Healthy (Type: EXPERIMENTAL): None
- PD (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Hyperbaric Oxygen Treatment as Adjuvant Treatment for Frost Injury

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Age 18-70. Frost damage grade II-IV. Inclusion is needed within 48 hours from time of damage.~Exclusion Criteria:~* Pregnancy. Ventilator treatment. Problems with equalizing. High grade heart failure. Chronic obstructive lung disease of high grade. Treatment over 3 days after time of damage. Serious claustrophobia/psychiatric illness.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Hyperbaric oxygen treatment (Type: EXPERIMENTAL): Hyperbaric oxygen treatment in an hyperbaric oxygen treatment chamber on an recognized treatment table.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Onabotulinum Dose Comparison in Chronic Migraine Superior to 100 Units?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Chronic migraine headache - Diagnostic criteria:~A. Headache (tension-type-like and/or migraine-like) on 15 days per month for \>3 months2 and fulfilling criteria B and C B. Occurring in a patient who has had at least five attacks fulfilling criteria B-D for 1.1 Migraine without aura and/or criteria B and C for 1.2 Migraine with aura~C. On 8 days per month for \>3 months, fulfilling any of the following 3 :~1. criteria C and D for 1.1 Migraine without aura~2. criteria B and C for 1.2 Migraine with aura~3. believed by the patient to be migraine at onset and relieved by a triptan or ergot derivative D. Not better accounted for by another ICHD-3 diagnosis. -~Exclusion Criteria:~Previous exposure at any time to any botulinum toxin serotype Pregnancy, breastfeeding or plans to become pregnant within 6 months Age \<18 years Failure to complete at least 20 days of headache diary in the 28 day baseline period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Group A 100U (Type: EXPERIMENTAL): None
- Group A 155U (Type: EXPERIMENTAL): None
- Group B 100U (Type: EXPERIMENTAL): None
- Group B 155 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Pain Perception During Vulvar Biopsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Females above age 18 presenting to Duke Gynecology Oncology clinic for vulvar biopsy~* Able to provide informed consent in English and agree to the risks of the study~Exclusion Criteria:~* Not able to provide informed consent~* Vulvar biopsy on a hair bearing surface

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 89 Years
- Healthy Volunteers: f

Study Arms:
- EMLA (Type: ACTIVE_COMPARATOR): None
- Lidocaine (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: GLP-1 CellBeads® for the Treatment of Stroke Patients With Space-occupying Intracerebral Hemorrhage

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of intracerebral hemorrhage or subarachnoid hemorrhage in conjunction with ICH by cranial computed tomography (CCT) or Magnetic Resonance Tomography (MRT)~* Patients who need by judgement of a clinical neurologist or neurosurgeon surgical removal of the blood clot due to its space-occupying effects~* Age greater or equal 18 years for men~* Age greater or equal 18 years for women if confirmed infertility (e.g. hysterectomy or surgical sterilisation at least 3 months before study start)~* For all other women age greater or equal 50 years with last menstrual bleeding at least one year before study start~* Minimum hematoma diameter of 2 cm as measured in baseline CCT or MRT~* Signed, written informed consent of patient or consent/assertion from the patient's legally acceptable representative/affiliated if the patient is unable to provide informed consent~Exclusion Criteria:~* Participation in any other clinical trial within the past 3 months or ongoing~* Occurrence of inconsistency with initial diagnosis at baseline during surgery of the patient leading to unfulfilled inclusion criterion Hemorrhage secondary to tumour or trauma~* Patients with a cerebellar hemorrhage or extension of a supratentorial hemorrhage into the brainstem~* Patients with severe pre-existing physical or mental disability or severe comorbidity that interferes with the assessment of outcome~* Allergy to contrast media (MRT)~* Acute infection~* Muscular, neurological, or vascular insufficiency of the respective tissue~* Polypropylene incompatibility~* Acute immunosuppressive medication~* Patient after organ transplantation~* Patient with immune depression~* Patients with a high probability of spontaneous recovery or showing rapidly improving signs~* Patients with extensive intracranial hemorrhages or with deep hemispheric localisation of the clots~* Patients whose diagnosis of ICH is uncertain

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- GLP-1 CellBeads (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Faecal Incontinence With Sacral Nerve Stimulation - Improved Function With Stimulation Bilaterally?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Informed Consent~* Diagnosed with idiopathic faecal incontinence and planned sacral nerve stimulation~* Age\> 40 years normal sigmoid/colonoscopic prior to operation~Exclusion Criteria:~* Pregnant or breastfeeding~* Patients who are not deemed able to follow the planned testing program, including mental illness or mentally unstable patients~* Medication with known effects on gastrointestinal motility, thyroid disease, diabetes, coeliaki, neurological disorders.~* Irritable Bowel Syndrome

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dextra (Type: EXPERIMENTAL): Unilateral sacral nerve stimulation dextra for 4 weeks
- Sinistra (Type: EXPERIMENTAL): Unilateral sacral nerve stimulation sinistra 4 weeks
- Bilateral (Type: EXPERIMENTAL): Bilateral sacral nerve stimulation 4 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Endoscopic Therapy of Malignant Bile Duct Strictures

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Documented malignant biliary obstruction requiring ERCP guided stenting~Exclusion Criteria:~* Coagulopathy (INR \> 2.0 or PTT \> 100 sec or platelet count \< 50,000)~* Evidence of high-grade symptomatic duodenal obstruction~* Poor performance status~* Active suppurative cholangitis~* Complex stenoses will not be eligible for the trial~* Patients without access to duodenum or ampulla are not candidates for ERCP and stenting~* Candidates for a Whipple resection~* Patients who do not speak English

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Radiofrequency ablation catheter

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Sedasys Post Approval Study Users Response to System Alarms

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* American Society of Anesthesiologists (ASA) I and II~* male and female~* Scheduled for routine colonoscopy or EGD~* ≥18 years of age~* Able to read, speak, and understand English~Exclusion Criteria:~* Physical or psychological condition which would impair trial participation, at the discretion of the PI~* BMI ≥ 35~* Pregnancy or lactation~* Known or suspected hypersensitivity to propofol or fentanyl~* Use of a fentanyl patch~* Allergies to eggs, egg products soybeans or soy products~* Diagnosis of sleep apnea~* Gastroparesis~* Full stomach at the time of procedure~* Participation in any other investigational device or drug study within 30 days of enrollment

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- SEDASYS System (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: safety issues
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Post-dural Puncture Headache in Postpartum Patients: Sphenopalatine Ganglion Block to Epidural Blood Patch.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria~1. Age 18 years or age or greater~2. Postpartum obstetric parturient who was previously admitted to UCH.~3. Diagnosis of post-dural puncture headache based on the International Classification of Headache Disorders:~   1. Dural puncture has been performed~  2. Headache has developed within 5 days of the dural puncture~  3. Not better accounted for by another ICHD-3 diagnosis.~  4. Occurring immediately or within seconds of assuming an upright position and resolving quickly (within 1 minute) after lying horizontally.~Exclusion Criteria~1. Refusal to participate in the study~2. Placement of an EBP within the past 5 days~3. Allergy and/or intolerance to any the study materials~4. Contraindications to an EBP~5. Plan for therapeutic anticoagulation post-partum

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- Sphenopalatine Ganglion Block (Type: EXPERIMENTAL): Sphenopalatine Ganglion Block: The patient is placed in the supine position. Four cc of 2% viscous lidocaine is placed to the level of the sphenopalatine ganglion with a 20 gauge angiocatheter along sterile swabs which were placed carefully into the patients nostrils bilaterally and lateral to the middle turbinate. It will be documented that the patient has no pain or paresthesia during or after the procedure. The swabs are withdrawn after 30 minutes.
- Epidural blood patch (Type: ACTIVE_COMPARATOR): Epidural Blood Patch: The patient is positioned in the sitting or lateral positon. Using aseptic technique, 20mL of autologous blood is drawn by a trained practitioner. The epidural placement is performed by a trained practitioner using aseptic technique and the vertebral space accessed is at or immediately below the original neuraxial placement. After entrance into the epidural space is confirmed with loss of resistance technique to either air or saline, 15-20 milliliters of sterile autologous venous blood is injected. After the procedure the patient rests supine for at least 1 hour. Patients are instructed to avoid heavy lifting, abdominal straining, or coughing for at least 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: lack of efficacy
Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Chemotherapy Influence on Clinical and Biological Markers of Ovarian Reserve

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Women volunteers treated by chemotherapy,~* ≥ 18 and ≤ 35 years old~* Regular menstrual cyclicity, between 25 and 35 days~* Social security affiliation~* Signed informed consent~Exclusion Criteria:~* Women \< 18 and \> 35 years old~* Pregnancy~* Emergent treatment necessity~* No social security affiliation~* Virgin patients

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: OTHER): systemic lupus erythematosus
- 2 (Type: OTHER): breast cancer
- 3 (Type: OTHER): Hodgkin disease

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Will Glucarpidase After Methotrexate Treatment for Bone Sarcoma Lead to Fewer Side Effects and Reduce Chemotherapy Delays?

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Written informed consent from patient or parent/guardian Diagnosis of high grade osteosarcoma, localised or metastatic or high grade osteosarcoma as a second malignancy or spindle cell sarcoma of bone or relapsed high grade osteosarcoma Ability to comply with study and follow up procedures (WHO performance scale 0-2) No concomitant anti-cancer or investigational drugs during the study and complete resolution of toxicity related to previous treatment Life expectancy of at least 3 months Haematopoietic function: Absolute neutrophil count ≥1 x109/L, Platelets ≥75 x109/L Hepatic function: Bilirubin ≤1.5 x ULN Renal function: Glomerular Filtration Rate (radioisotope) ≥ 70 ml/min/1.73m2~Exclusion Criteria:~Previous treatment with glucarpidase Pregnant or breast feeding women (patients with reproductive potential of either gender must use contraception\*) Concomitant treatment with agents which interact with methotrexate metabolism or excretion Serous effusions, including ascites and pleural effusions

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- M (Type: ACTIVE_COMPARATOR): Methotrexate (12 g/m2 x 1, intravenously) with standard folinic acid rescue~In arm A patients will receive cycle M first followed by cycle GluM. Cycle M starts with course M1 on day 1 followed by course M2 planned for day 8. Cycle GluM starts with course GluM1 on day 1 followed by GluM2 planned for day 8. Cycle GluM will not start for a minimum of 14 days from the beginning of course M2, or until bone marrow, renal and hepatic functions have completely recovered and the patient is clinically ready to receive further chemotherapy .
- GluM (Type: EXPERIMENTAL): Methotrexate (12 g/m2 x 1, intravenously) with folinic acid and glucarpidase rescue (50 units/kg x 1, intravenously).~In arm B, patients will receive cycle GluM first followed by cycle M. Cycle GluM starts with course GluM1 on day 1 followed by GluM2 planned for day 8.Cycle M starts with course M1 on day 1 followed by course M2 planned for day 8. Cycle M will not start for a minimum of 14 days from the beginning of course GluM2, or until bone marrow, renal and hepatic function have completely recovered and the patient is clinically ready to receive further chemotherapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues